Vas Narasimhan, Novartis CEO (Gian Ehrenzeller/Keystone via AP)

No­var­tis pulls the plug on UK-based car­dio­vas­cu­lar study

No­var­tis is call­ing off a UK-based tri­al for Leqvio in the pri­ma­ry pre­ven­tion of car­dio­vas­cu­lar events in pa­tients with high cho­les­terol, the com­pa­ny con­firmed on Wednes­day.

The Swiss phar­ma gi­ant made the de­ci­sion af­ter “care­ful eval­u­a­tion,” a spokesper­son told End­points News via email. The tri­al, dubbed ORI­ON-17, was planned in part­ner­ship with Eng­land’s Na­tion­al Health Ser­vice (NHS) and was part of the com­pa­ny’s strat­e­gy to es­tab­lish Leqvio as a stan­dard of care in car­dio­vas­cu­lar dis­ease man­age­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.